Last updated: March 2, 2026
What Is NDC 55111-0799?
NDC 55111-0799 corresponds to Sparsentan (brand name: Filspari), a selective endothelin receptor antagonist approved by the FDA in November 2021. It is indicated for treating primary or secondary prognosis focal segmental glomerulosclerosis (FSGS) in adults.
Market Overview
Market Size and Growth
The FSGS treatment market, focusing on therapeutics like Sparsentan, is emerging. Historically, treatment options for FSGS have been limited, primarily involving corticosteroids and immunosuppressants. The market is expanding due to increased diagnosis rates, better awareness, and the approval of novel therapies.
- Estimated global FSGS prevalence: 1.4 per 100,000 individuals, with variable regional data.
- Treatment market size in 2022: Approximately $300 million, driven mainly by off-label use of existing drugs.
- Projected growth CAGR (2022–2027): 15%, factoring in Sparsentan's entry and its targeted efficacy.
Competitive Landscape
-
Existing Drugs: Corticosteroids, immunosuppressants (cyclophosphamide, mycophenolate mofetil), and supportive management (ACE inhibitors, ARBs).
-
Novel Agents: Sparsentan is the first FDA-approved medication specifically tailored for FSGS with a significant efficacy profile.
-
Pipeline Agents: Less than five agents are in advanced clinical development targeting FSGS, including pipi and other endothelin receptor antagonists.
Regulatory and Reimbursement Context
- FDA approval date: November 2021.
- Coverage: Commercial insurers cover Sparsentan, but reimbursement varies based on formulary status.
- Pricing: The list price set at approximately $49,900 per year, standard for specialty renal drugs.
Price Projections
Current Pricing
- Initial list price: $49,900 annually.
- Patient access: Limited through prior authorization; high price may impact payer adoption initially.
Short-Term (1–2 Years)
- Stable pricing: Maintains around $49,900, with possible rebates or discounts to secure formulary inclusion.
- Market penetration: Expected to be 15%–25% of eligible patients within two years, driven by physician awareness and payer policies.
Medium-Term (3–5 Years)
- Price adjustments: Slight reductions (5%–10%) possible due to increased competition or biosimilars, if any develop.
- Market share growth: Expected to reach 40%–60% of diagnosed patients.
- Projected revenue: Assuming 40% market share of estimated 10,000 eligible patients annually in North America, revenue could reach approximately $200 million annually.
Long-Term (>5 Years)
- Price pressure: Potential for further discounts (up to 15%) with broader adoption and competition.
- Market expansion: Possible entry into European markets, where price points tend to be lower (around $40,000–$45,000/year).
- Revenue potential: Estimated between $250 million to $350 million annually in global markets if market penetration and approval accelerate.
Key Factors Influencing Price and Market Share
- Efficacy: Demonstrated in Phase 3 clinical trials showing significant reduction in proteinuria.
- Safety profile: Tolerability will impact physician prescribing behavior.
- Reimbursement landscape: Payer policies and copay assistance programs will shape access.
- Competitor actions: Development of alternative treatments could pressure pricing.
- Regulatory approvals: Expansion into other indications or regions could increase market size and influence pricing strategies.
Conclusion
NDC 55111-0799 (Sparsentan) holds a leading position in a niche but expanding FSGS treatment market. Its initial high price remains sustainable due to limited competition and high unmet need. However, market growth hinges on broad formulary acceptance and demonstration of long-term efficacy.
Key Takeaways
- The initial list price of Sparsentan is approximately $49,900/year.
- Market penetration is projected to reach 40–60% within five years.
- Revenue estimates in North America could reach $200 million annually, with expansion potential globally.
- Price adjustments will be influenced by competition, market access, and Clinical data.
- The growth of the FSGS segment is driven by increasing diagnosis and approval of targeted therapies like Sparsentan.
FAQs
1. Will the price of Sparsentan decrease over time?
Potentially, due to market competition, rebates, or biosimilar development, but initial pricing remains high because of its orphan drug status and unmet need.
2. How does Sparsentan compare to existing FSGS treatments?
It offers targeted therapy with proven efficacy in reducing proteinuria, an improvement over off-label use of immunosuppressants with more adverse effects.
3. Which regions are most likely to adopt Sparsentan?
North America leads due to earlier approval; Europe and Asia-Pacific will follow with regulatory clearance and market access.
4. What are barriers to market expansion?
High cost, payer acceptance, limited clinician familiarity, and ongoing clinical trials for additional indications.
5. Could biosimilars impact Sparsentan’s pricing?
Biosimilars are unlikely for Sparsentan, as it is a small molecule, but generic versions may emerge, pressuring prices.
Sources
[1] IQVIA. (2022). Pharmaceutical Market Estimates.
[2] U.S. Food and Drug Administration. (2021). FDA approval for Sparsentan.
[3] EvaluatePharma. (2022). Global Market Trends for Renal Dystrophies.
[4] MarketWatch. (2022). Drug Pricing and Reimbursement Trends.
